



Passion for Innovation.
Compassion for Patients.™

IASLC 2019 World Conference on Lung Cancer
Industry Symposium

Targeting HER Pathways in Advanced NSCLC: Emerging Concepts and Future Opportunities



Chair: Dr. Frances Shepherd

Sunday 8th September 2019
07:00-08:00

Hilton Head (1978), Hall 8, Ground Floor, Fira Barcelona Gran Via

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

Agenda

Sunday 8th September 2019, 07:00-08:00
Hilton Head (1978), Hall 8, Ground Floor
Fira Barcelona Gran Via
Chair: Dr. Frances Shepherd

IASLC 2019 World Conference on Lung Cancer
Industry Symposium

Targeting HER Pathways in Advanced NSCLC: Emerging Concepts and Future Opportunities

Faculty

Dr. Frances Shepherd

Princess Margaret Cancer Centre, Toronto, Canada

Dr. Suresh Ramalingam

Winship Cancer Institute, Atlanta, USA

Dr. Egbert Smit

Netherlands Cancer Institute, Amsterdam, The Netherlands

07:00-07:10	Welcome and Introduction Targeting HER2 Pathways in Oncogene Driven Advanced NSCLC: The Continuing Evolution of Personalised Treatment	Frances Shepherd
07:10-07:30	The Role of Antibody Drug Conjugates (ADCs) in Thoracic Cancer: Current State-of-the-Art	Suresh Ramalingam
07:30-07:50	Targeting HER Pathways in Advanced NSCLC: Emerging Data and Future Prospects	Egbert Smit
07:50-08:00	Q&A: Audience & Wrap-Up	All Faculty Members

Programme Overview

Providing new options for patients who have exhausted currently available options represents a critical unmet need for patients with non-small cell lung cancer (NSCLC), and is also a key objective for treating physicians. As the range of treatment options for NSCLC increases, so does the need to carefully consider the evidence for selection of treatments in order to optimise clinical outcomes. Targeting the HER pathways is becoming an increasingly important focus for such patients.

At this Symposium, an international faculty of experts will discuss the evolution of treatment for NSCLC with regard to HER pathway genes and the emerging data with antibody-drug conjugates in these patients.



Passion for Innovation.
Compassion for Patients.™

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.